Focused Ultrasound for Metastatic Colorectal Cancer: First Patient Enrolled in Clinical Trial
Details
Oxford-based OxSonics Therapeutics announced that the first patient was dosed in a clinical trial evaluating their SonoTran platform for treating colorectal cancer that has spread to the liver.
The SonoTran platform is designed to actively pump unmodified oncology drugs at the site of solid tumours to enhance their effectiveness.
Nearly 50 patients with liver metastases will be enrolled at Oxford University Hospitals.
OxSonics Therapeutics is a clinical-stage oncology company that has developed an ultrasound-based drug delivery platform.
Their SonoTran Platform uses low-intensity focused ultrasound combined with injectable ‘SonoTran Particles’ to enhance the dose and penetration of unmodified cancer drugs into solid tumors to enable more effective therapies for cancer patients.
